Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
ObjectiveCurrent knowledge on the actions of tofacitinib on cytokine signaling pathways in rheumatoid arthritis (RA) is based on in vitro studies. Our study is the first to examine the effects of tofacitinib treatment on Janus kinase (JAK) - signal transducer and activator of transcription (STAT) pa...
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Frontiers Media S.A.
2021-09-01
|
| 叢編: | Frontiers in Immunology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.738481/full |